Real Time Touch



new TOP 200 Companies filing patents this week

new Companies with the Most Patent Filings (2010+)




Real Time Touch

Lupin Limited patents


Recent patent applications related to Lupin Limited. Lupin Limited is listed as an Agent/Assignee. Note: Lupin Limited may have other listings under different names/spellings. We're not affiliated with Lupin Limited, we're just tracking patents.

ARCHIVE: New 2018 2017 2016 2015 2014 2013 2012 2011 2010 2009 | Company Directory "L" | Lupin Limited-related inventors


Polymorphic forms of pitavastatin sodium

The present invention is directed to polymorphic forms of pitavastatin sodium and processes for preparation of the same.. . ... Lupin Limited

Stable pharmaceutical composition of tnfr:fc fusion protein

The present invention relates to the stable pharmaceutical compositions comprising tumor necrosis factor receptor fc fusion protein (tnfr:fc). More particularly, it relates to the stable pharmaceutical compositions comprising tumor necrosis factor receptor fc fusion protein (tnfr:fc), phosphate-citrate buffer. ... Lupin Limited

Refolding process for antibody's fragments

A refolding process of ranibizumab is disclosed wherein the solubilized solution of heavy chain and/or light chain of ranibizumab treated with refolding buffer under suitable conditions including ph, temperature and incubation period and the ph and temperature shift is performed at suitable interval to obtain high quality and quantity of refolded protein.. . ... Lupin Limited

Process for preparation of apremilast and novel polymorphs thereof

The present invention provides an improved process for preparation of an intermediate of apremilast. The present invention also provides an improved process for preparation of apremilast. ... Lupin Limited

Process for the preparation of pharmaceutical grade ferric citrate

A one-pot process is disclosed for the preparation of pharmaceutical grade ferric citrate that includes preparing a ferric hydroxide slurry followed by treatment with a citrate ion source to yield pharmaceutical grade ferric citrate.. . ... Lupin Limited

Process for preparation of cysteamine bitartrate

The present invention provides process for preparation of cysteamine bitartrate comprising reacting cysteamine or its salt with tartaric acid. The present invention further provides crystalline form l1 of cysteamine bitartrate having characteristic diffraction peaks at 10.36, 14.54, 17.23, 18.03, 19.24, 20.76, 21.20, 22.02, 23.37, 23.64, 27.71, 28.28, 29.26, 31.33, 32.84, 33.83, 35.51, 36.74±0.2 degree two theta in an x-ray diffraction pattern and process for preparation thereof. ... Lupin Limited

Sulfonamide compounds as voltage-gated sodium channel modulators

The present invention relates to sulfonamide compounds formula (i) wherein the substituents are as described herein, and their use in a medicine for the treatment of diseases, disorders associated with the inhibition of voltage-gated sodium channels (vgsc) particularly nav1.7. It further relates to the compounds herein and their pharmaceutically acceptable salts thereof, pharmaceutical compositions thereof useful in treating diseases, disorders, syndromes and/or conditions associated with the inhibition of voltage-gated sodium channels (vgsc) particularly nav1.7. ... Lupin Limited

Process for preparation of cinacalcet intermediate and cinacalcet hydrochloride

The present invention provides one pot process for preparation of highly pure unsaturated cinacalcet hydrochloride (ii) comprising: i) converting 3-(trifluromethyl) cinnamic acid (iii) into 3-(3-(trifluoromethyl)phenyl)prop-2-en-1-ol (iv), ii) converting 3-(3-(trifluoromethyl)phenyl)prop-2-en-1-ol (iv) to compound (v), wherein r is cl, br, i, tosylate and mesylate, formula (v) iii) reacting compound (v) with (r)-1-(1-naphthyl) ethylamine (vi) in presence of base followed by treatment with hydrochloric acid. The present invention further provides conversion of unsaturated cinacalcet hydrochloride (ii) to cinacalcet hydrochloride (i).. ... Lupin Limited

Compositions of diclofenac acid

The present invention provides solid oral pharmaceutical compositions comprising wet milled diclofenac acid and one or more pharmaceutically acceptable excipients and process for preparation thereof. The present invention particularly relates to solid oral pharmaceutical compositions comprising wet milled diclofenac acid with median particle size of less than 1000 nm. ... Lupin Limited

Novel crystalline form of eslicarbazepine

The present invention provides novel crystalline form l1 of eslicarbazepine characterized by diffraction peaks at 7.09, 10.03, 11.73, 14.12, 16.94, 18.03, 20.00, 23.20, 23.58, 23.76, 26.05, 26.52, 28.37, 29.90, 31.42±0.2 degree two theta in an x-ray diffraction pattern. The present invention further provides conversion of crystalline form l1 of eslicarbazepine to eslicarbazepine acetate.. ... Lupin Limited

Process for the preparation of efinaconazole

The present invention provides an improved process for the preparation of efinaconazole in higher yield by the ring-opening addition reaction of epoxytriazole with 4-methylenepiperidine or its acid addition salt under mild conditions without using a large excess of 4-methylenepiperidine in the presence of an alkali or an alkaline earth metal halide.. . ... Lupin Limited

Salts of obeticholic acid

The invention relates to salts of obeticholic acid, their amorphous and crystalline polymorphic form and processes for preparation thereof.. . ... Lupin Limited

Process for the preparation of vortioxetine

Disclosed herein a process for the isolation of intermediate of vortioxetine in a solid state form and an improved, commercially viable and industrially advantageous process for the preparation of vortioxetine or a pharmaceutically acceptable salt thereof, in high yield and purity.. . ... Lupin Limited

Process for preparation of polymorphic form of mirabegron

The present invention is directed to process for preparation of α-form crystal of mirabegron, (r)-2-(2-aminothiazol-4-yl)-n-(4-(2-((2-hydroxy-2-phenylethyl) amino) ethyl) phenyl) acetamide of formula (1).. . ... Lupin Limited

10/26/17 / #20170304299

Oxazoline and isoxazoline derivatives as crac modulators

The present invention relates to compounds of formula (i) along with processes for their preparation that are useful for treating, preventing and/or managing the diseases, disorders, syndromes or conditions associated with the modulation of crac. The invention further relates to methods of treating, preventing managing and/or lessening the diseases, disorders, syndromes or conditions associated with the modulation of crac of formula (i).. ... Lupin Limited

09/14/17 / #20170259241

A manufacturing process for an iron containing adsorbent

The present invention is directed towards a manufacturing method for an iron containing phosphate adsorbent. Said iron containing phosphate adsorbent is characterized by a psd d(0.9) in the range of 20 μm to 80 μm, a bet active surface area less than 15 m2/gm and phosphate binding in the range of 35 to 60 mg/gm.. ... Lupin Limited

08/03/17 / #20170218007

A process for the preparation of nucleoside phosphoramidate

The present invention pertains to process for preparing nucleoside phosphoramidate and its intermediate. The present invention provides novel intermediate, its process for preparation and its use for the preparation of sofosbuvir.. ... Lupin Limited

08/03/17 / #20170217894

Polymorphic forms of pitavastatin sodium

The present invention is directed to polymorphic forms of pitavastatin sodium and processes for preparation of the same.. . ... Lupin Limited

06/29/17 / #20170183292

A process for preparation of levothyroxine and salts thereof

The present invention relates to a process for the preparation of levothyroxine and salts thereof. The process described in the present invention provides increase in the yields and purity comprising the use of sodium iodide and sodium hypochlorite as iodinating agent.. ... Lupin Limited

06/08/17 / #20170159060

Dual cistronic bacterial expression system

The present invention relates to the dual, independent cistron expression system in a single vector for the production of protein of interest proteins and peptides expressed as insoluble inclusion bodies formed in the bacteria e. Coli. ... Lupin Limited

06/01/17 / #20170152298

Process for the purification of tnfr:fc fusion protein

The present invention relates to the purification of tnfr:fc fusion protein. More specifically related to process of purification of tnfr:fc fusion protein wherein the hcp is reduced. ... Lupin Limited

05/18/17 / #20170137421

Quinolizinone derivatives as pi3k inhibitors

Disclosed are compounds of formula (i), their tautomeric forms, stereoisomers, and pharmaceutically acceptable salts thereof, wherein r1-r4, and n are as defined in the specification, pharmaceutical compositions including a compound, tautomer, stereoisomer, or salt thereof, and methods of treating or preventing diseases or disorders, for example, cancer, that are amenable to treatment or prevention by inhibiting the pi3k enzyme of a subject.. . ... Lupin Limited

05/18/17 / #20170137415

Sulfonamide compounds as voltage gated sodium channel modulators

The present invention relates to the compound of formula (i) wherein the substituents are as described herein, and their use in a medicine for the treatment of diseases, disorders associated with the inhibition of voltage-gated sodium channels (vgsc) particularly nav1.7. It further relates to the compounds herein and their pharmaceutically acceptable salts thereof, pharmaceutical compositions thereof useful in treating diseases, disorders, syndromes and/or conditions associated with the inhibition of voltage-gated sodium channels (vgsc) particularly nav1.7. ... Lupin Limited

04/27/17 / #20170112840

Heterocyclyl compounds

The present invention is related to heteroaryl compounds as mek inhibitors. The invention includes heteroaryl compounds of formula i, their tautomers and pharmaceutically acceptable salts, combinations with suitable medicament and pharmaceutical compositions thereof. ... Lupin Limited

04/20/17 / #20170107553

Cell culture process for producing a protein

The invention provides the mammalian cell culture process for the production of monoclonal antibodies and fusion proteins wherein the mammalian cell is cultured in suitable cell culture conditions specifically maintaining monophasic temperature.. . ... Lupin Limited

04/13/17 / #20170101408

Heterocyclyl compounds as mek inhibitors

The present disclosure is related to heteroaryl compounds as mek inhibitors. These compounds include heteroaryl compounds of formula i, their pharmaceutically acceptable salts, combinations with suitable medicament and pharmaceutical compositions thereof. ... Lupin Limited

02/02/17 / #20170027863

Oral controlled release pharmaceutical compositions of bepotastine

The present invention relates to oral controlled release pharmaceutical compositions comprising bepotastine. The oral controlled release pharmaceutical composition comprises bepotastine or pharmaceutically acceptable salts thereof and at least one release controlling agent. ... Lupin Limited








ARCHIVE: New 2018 2017 2016 2015 2014 2013 2012 2011 2010 2009



###

This listing is an abstract for educational and research purposes is only meant as a recent sample of applications filed, not a comprehensive history. Freshpatents.com is not affiliated or associated with Lupin Limited in any way and there may be associated servicemarks. This data is also published to the public by the USPTO and available for free on their website. Note that there may be alternative spellings for Lupin Limited with additional patents listed. Browse our Agent directory for other possible listings. Page by FreshPatents.com

###